Scribe Therapeutics Procures $20M in Series A

Scribe Therapeutics, the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, announced a research collaboration with Biogen Inc. (Nasdaq:BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).

Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz.